 |
Myriad Genetics to Present at Lazard Capital Markets Sixth Annual Healthcare Conference
Nov 4, 2009
|
12.8 KB |
|
| |
SALT LAKE CITY, Nov 4, 2009 (GlobeNewswire via COMTEX News Network) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that Gregory C. Critchfield, M.D., President of Myriad Genetic Laboratories, Inc., is scheduled to present an overview of the Company at the Lazard Capital Markets Sixth Annual Healthcare Conference, at 9:30 a.m. Eastern on Nov...
|
|
Myriad Genetics Reports First Quarter Fiscal 2010 Financial Results
Nov 3, 2009
|
18.8 KB |
|
| |
SALT LAKE CITY, Nov 3, 2009 (GlobeNewswire via COMTEX News Network) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today reported financial results for its fiscal first quarter ended September 30, 2009.
Molecular diagnostic revenue increased 22% to $85.1 million in the fiscal first quarter ended September 30, 2009, compared with $70.0 million in the sa...
|
|
Myriad Genetics Acquires Exclusive Rights to Pancreatic Cancer Gene Patents From Johns Hopkins
Oct 15, 2009
|
15.7 KB |
|
| |
SALT LAKE CITY, Oct 15, 2009 (GlobeNewswire via COMTEX News Network) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced it has obtained from Johns Hopkins University a world-wide, exclusive license to patents covering mutations in the PALB2 gene that increase an individual's risk for developing pancreatic cancer later in life.
These patents...
|
|
Myriad Genetics to Report Fiscal 2010 First Quarter Financial Results On November 3
Oct 13, 2009
|
12.1 KB |
|
| |
SALT LAKE CITY, Oct 13, 2009 (GlobeNewswire via COMTEX News Network) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that it will release its fiscal 2010 first quarter financial results at the close of market on Tuesday, November 3, 2009.
The Company will host a conference call on Tuesday, November 3, at 4:30 p.m. Eastern to review the f...
|
|
Myriad Genetics to Present At the Fourth Annual JMP Securities Healthcare Focus Conference
Sep 22, 2009
|
12.8 KB |
|
| |
SALT LAKE CITY, Sep 22, 2009 (GlobeNewswire via COMTEX News Network) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that Peter D. Meldrum, President and CEO, is scheduled to present an overview of the Company at The Fourth Annual JMP Securities Healthcare Focus Conference, at 9:00 a.m. Eastern on October 5, 2009, at the New York Palace Hote...
|
|
Myriad Genetics Elects Louise Phanstiel and Lawrence Best to Its Board of Directors
Sep 21, 2009
|
14.8 KB |
|
| |
SALT LAKE CITY, Sep 21, 2009 (GlobeNewswire via COMTEX News Network) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that it has elected Louise Phanstiel and Lawrence Best to its Board of Directors, effective September 16, 2009, increasing the size of the Company's board from eight members to 10.
Ms. Phanstiel held several important posi...
|
|
Myriad Genetics Launches Public Awareness Campaign in Five Midwest States to Reach Women with Increased Risk of Hereditary Breast and Ovarian Cancer
Sep 14, 2009
|
13.4 KB |
|
| |
SALT LAKE CITY, Sept 14, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Myriad Genetics, Inc. (Nasdaq: MYGN) announced today that it has launched a hereditary breast and ovarian cancer Public Awareness Campaign in five Midwest states, including Illinois, Indiana, Kentucky, Missouri and Ohio. The initiative is a comprehensive effort designed...
|
|
Myriad Genetics to Present At the UBS Global Life Sciences Conference
Sep 8, 2009
|
12.8 KB |
|
| |
SALT LAKE CITY, Sep 8, 2009 (GlobeNewswire via COMTEX News Network) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that Peter D. Meldrum, President and CEO, is scheduled to present an overview of the Company at the UBS Global Life Sciences Conference, at 12:30 p.m. Eastern on September 22, 2009, at the Grand Hyatt Hotel in New York City.
...
|
|
Myriad Genetics to Present At The Morgan Stanley Global Healthcare Conference
Aug 31, 2009
|
12.8 KB |
|
| |
SALT LAKE CITY, Aug 31, 2009 (GlobeNewswire via COMTEX News Network) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that Peter D. Meldrum, President and CEO, is scheduled to present an overview of the Company at The Morgan Stanley Global Healthcare Conference, at 10:20 a.m. Eastern on September 14, 2009, at the Grand Hyatt Hotel in New York...
|
|
Myriad Genetics Reports Fiscal 2009 Financial Results
Aug 25, 2009
|
20.2 KB |
|
| |
SALT LAKE CITY, Aug 25, 2009 (GlobeNewswire via COMTEX News Network) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today reported financial results for its fourth quarter and fiscal year ended June 30, 2009. It should be noted that as a result of the successful spin off of the Company's pharmaceutical and research businesses on June 30, 2009, the Company'...
|
|
Myriad Genetics to Report Fiscal 2009 Fourth Quarter and Year-End Financial Results On August 25
Aug 3, 2009
|
10.5 KB |
|
| |
SALT LAKE CITY, Aug 3, 2009 (GlobeNewswire via COMTEX News Network) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that it will release its fiscal 2009 fourth quarter and year-end financial results at the close of market on Tuesday, August 25, 2009.
The company will host a conference call on Tuesday, August 25, at 4:30 p.m. Eastern to r...
|
|
Myriad Genetics Announces Completion of Spin Off of Its Research and Pharmaceutical Business
Jul 1, 2009
|
13.1 KB |
|
| |
SALT LAKE CITY, Jul 1, 2009 (GlobeNewswire via COMTEX News Network) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today the successful completion of the spin off of Myriad Pharmaceuticals, Inc. (Nasdaq:MYRX), and that Myriad Genetics has received a Private Letter Ruling from the Internal Revenue Service that the dividend of common stock of Myria...
|
|
Myriad Genetics Announces Preliminary Revenue Results for Fiscal 2009 Fourth Quarter, Full Year
Jun 30, 2009
|
11.3 KB |
|
| |
SALT LAKE CITY, UT, Jun 30, 2009 (MARKETWIRE via COMTEX News Network) -- Myriad Genetics, Inc. (NASDAQ: MYGN) today announced that, based on preliminary estimates, it anticipates reporting total molecular diagnostic revenue, which represents the bulk of the Company's revenue, of approximately $86 million for the fiscal 2009 fourth quarter ending Ju...
|
|
Myriad Genetics Announces Effectiveness of Myriad Pharmaceuticals Registration Statement on Form 10
Jun 11, 2009
|
10.3 KB |
|
| |
SALT LAKE CITY, UT, Jun 11, 2009 (MARKETWIRE via COMTEX News Network) -- Myriad Genetics, Inc. (NASDAQ: MYGN) today announced that, in connection with its proposed spin-off of Myriad Pharmaceuticals, Inc., the Securities and Exchange Commission has declared effective Myriad Pharmaceuticals' Registration Statement on Form 10.
Myriad Pharmaceutic...
|
|
Myriad Genetics Sets Record and Distribution Dates for Spin-Off of Myriad Pharmaceuticals
Jun 4, 2009
|
13.2 KB |
|
| |
SALT LAKE CITY, UT, Jun 04, 2009 (MARKETWIRE via COMTEX News Network) -- Myriad Genetics, Inc. (NASDAQ: MYGN) announced today that its Board of Directors has set the shareholder of record and distribution dates in connection with the spin-off of its wholly owned subsidiary, Myriad Pharmaceuticals, Inc. Shareholders of record of Myriad Genetics, Inc...
|
|
Myriad Genetics to Present at The Goldman Sachs 30th Annual Global Healthcare Conference and The 8th Annual Needham Life Sciences Conference
May 28, 2009
|
9.4 KB |
|
| |
SALT LAKE CITY, UT, May 28, 2009 (MARKET WIRE via COMTEX News Network) -- Myriad Genetics, Inc. (NASDAQ: MYGN) announced today that Gregory C. Critchfield, M.D., President of Myriad Genetic Laboratories, Inc., is scheduled to present an overview of the Company at The 8th Annual Needham Life Sciences Conference, at 11:00 a.m. EDT on June 10, 2009, a...
|
|
Myriad Genetics Reports Fiscal 2009 Third Quarter Financial Results
May 4, 2009
|
16.9 KB |
|
| |
SALT LAKE CITY, UT, May 04, 2009 (MARKET WIRE via COMTEX News Network) -- Myriad Genetics, Inc. (NASDAQ: MYGN) today reported financial results for the fiscal 2009 third quarter and nine-month period ended March 31, 2009.
For the third quarter of fiscal 2009, the Company posted a record net profit of $25.3 million, or $0.25 per diluted share, c...
|
|
New Study Published in CANCER Supports Use of BRACAnalysis Testing Across Broad Ethnic Populations
Apr 30, 2009
|
13.0 KB |
|
| |
SALT LAKE CITY, UT, Apr 30, 2009 (MARKET WIRE via COMTEX News Network) -- Myriad Genetics, Inc. (NASDAQ: MYGN) announced today that an article entitled "BRCA1 and BRCA2 Mutations in Women of Different Ethnicities Undergoing Testing for Hereditary Breast-Ovarian Cancer" will appear in the May 15, 2009 issue of the journal CANCER. The study demonstra...
|
|
Myriad Genetics to Present at Bank of America and Merrill Lynch 2009 Health Care Conference and the Eighth Annual JMP Securities Research Conference
Apr 28, 2009
|
10.4 KB |
|
| |
SALT LAKE CITY, UT, Apr 28, 2009 (MARKET WIRE via COMTEX News Network) -- Myriad Genetics, Inc. (NASDAQ: MYGN) announced today that Peter D. Meldrum, President and CEO, is scheduled to present an overview of the Company at the Bank of America and Merrill Lynch 2009 Health Care Conference, at 2:00 p.m. EDT on May 12, at The Palace Hotel in New York,...
|
|
Myriad Genetics Launches OnDose, Its Seventh Molecular Diagnostic Product
Apr 27, 2009
|
13.8 KB |
|
| |
SALT LAKE CITY, UT, Apr 27, 2009 (MARKET WIRE via COMTEX News Network) -- Myriad Genetics, Inc. (NASDAQ: MYGN) announced today the launch of OnDose(TM), the Company's seventh molecular diagnostic product. OnDose(TM) utilizes a unique, proprietary technology to measure a patient's exposure to the chemotherapy drug, 5-Fluorouracil (5-FU), to help onc...
|
|
|
